Northern Trust’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,063
| Closed | -$11.9K | – | 4663 |
|
|
2023
Q1 | $11.9K | Hold |
1,063
| – | – | ﹤0.01% | 4508 |
|
|
2022
Q4 | $12.1K | Hold |
1,063
| – | – | ﹤0.01% | 4556 |
|
|
2022
Q3 | $16K | Buy |
+1,063
| New | +$26.2K | ﹤0.01% | 4589 |
|
|
2022
Q2 | – | Sell |
-72
| Closed | -$30K | – | 4820 |
|
|
2022
Q1 | $30K | Hold |
72
| – | – | ﹤0.01% | 4622 |
|
|
2021
Q4 | $71K | Sell |
72
-51
| -41% | -$71.9K | ﹤0.01% | 4520 |
|
|
2021
Q3 | $237K | Buy |
123
+35
| +40% | +$79.2K | ﹤0.01% | 4099 |
|
|
2021
Q2 | $235K | Sell |
88
-284
| -76% | -$936K | ﹤0.01% | 4090 |
|
|
2021
Q1 | $1.55M | Sell |
372
-19
| -5% | -$103K | ﹤0.01% | 3381 |
|
|
2020
Q4 | $2.25M | Sell |
391
-14
| -3% | -$82.4K | ﹤0.01% | 3141 |
|
|
2020
Q3 | $2.46M | Sell |
405
-23
| -5% | -$132K | ﹤0.01% | 2958 |
|
|
2020
Q2 | $2.38M | Buy |
428
+360
| +529% | +$1.87M | ﹤0.01% | 2949 |
|
|
2020
Q1 | $253K | Buy |
68
+14
| +26% | +$80.3K | ﹤0.01% | 3626 |
|
|
2019
Q4 | $270K | Buy |
54
+19
| +54% | +$66.4K | ﹤0.01% | 3703 |
|
|
2019
Q3 | $83K | Buy |
35
+15
| +75% | +$37K | ﹤0.01% | 3956 |
|
|
2019
Q2 | $60K | Hold |
20
| – | – | ﹤0.01% | 4056 |
|
|
2019
Q1 | $62K | Hold |
20
| – | – | ﹤0.01% | 4010 |
|
|
2018
Q4 | $24K | Hold |
20
| – | – | ﹤0.01% | 4135 |
|
|
2018
Q3 | $15K | Sell |
20
-1
| -5% | -$732 | ﹤0.01% | 4235 |
|
|
2018
Q2 | $20K | Hold |
21
| – | – | ﹤0.01% | 4215 |
|
|
2018
Q1 | $105K | Buy |
21
+2
| +11% | +$13.2K | ﹤0.01% | 3968 |
|
|
2017
Q4 | $102K | Buy |
19
+5
| +36% | +$46.6K | ﹤0.01% | 3968 |
|
|
2017
Q3 | $125K | Hold |
14
| – | – | ﹤0.01% | 3901 |
|
|
2017
Q2 | $105K | Sell |
14
-60
| -81% | -$415K | ﹤0.01% | 3969 |
|
|
2017
Q1 | $477K | Buy |
74
+3
| +4% | +$15.1K | ﹤0.01% | 3551 |
|
|
2016
Q4 | $809K | Hold |
71
| – | – | ﹤0.01% | 3410 |
|
|
2016
Q3 | $986K | Hold |
71
| – | – | ﹤0.01% | 3346 |
|
|
2016
Q2 | $1.08M | Buy |
71
+5
| +8% | +$68.5K | ﹤0.01% | 3319 |
|
|
2016
Q1 | $824K | Buy |
66
+14
| +27% | +$181K | ﹤0.01% | 3317 |
|
|
2015
Q4 | $1M | Buy |
52
+1
| +2% | +$15.8K | ﹤0.01% | 3328 |
|
|
2015
Q3 | $692K | Buy |
51
+41
| +410% | +$728K | ﹤0.01% | 3413 |
|
|
2015
Q2 | $179K | Buy |
10
+3
| +43% | +$64K | ﹤0.01% | 3800 |
|
|
2015
Q1 | $136K | Buy |
7
+2
| +40% | +$35.1K | ﹤0.01% | 3972 |
|
|
2014
Q4 | $64K | Hold |
5
| – | – | ﹤0.01% | 4064 |
|
|
2014
Q3 | $76K | Buy |
+5
| New | +$77.2K | ﹤0.01% | 4076 |
|
Other funds holding AGRX
AC
TRCT
IA
Northern Trust's AGRX Position: Q2 2023 in Review
Northern Trust sold out of Agile Therapeutics (AGRX) in Q2 2023, closing a stake of 1,063 shares — an estimated $11.9K sold.
Northern Trust first reported a position in AGRX in Q3 2014 and held it in 34 quarters. The position peaked at $2.46M in Q3 2020. 16 funds tracked by Wall St. Rank hold AGRX as of Q2 2023.
- Northern Trust reported no remaining Agile Therapeutics position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 1,063 Agile Therapeutics shares in Q2 2023, an estimated $11.9K.
- Northern Trust first reported a position in Agile Therapeutics in Q3 2014 and held it in 34 quarters.
- Northern Trust's Agile Therapeutics position peaked at $2.46M in Q3 2020.
- 16 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.